Navigation Links
IDEXX Laboratories Announces First Quarter Results
Date:4/24/2009

s $3,285 $24,768 Net effect of exchange rate changes (1,603) 2,689 Net increase (decrease) in cash and cash equivalents 7,427 (140) Cash and cash equivalents, beginning of period 78,868 60,360 Cash and cash equivalents, end of period $86,295 $60,220 IDEXX Laboratories, Inc. and Subsidiaries Free Cash Flow Amounts in thousands (Unaudited) Three Months Ended March 31, March 31, 2009 2008 Free Cash Flow: Net cash provided (used) by operating activities $12,624 $(2,789) Financing cash flows attributable to tax benefits from exercise of stock options 161 2,384 Purchase of fixed assets (9,114) (17,049) Acquisition of equipment leased to customers (188) (226) Free cash flow $3,483 $(17,680) Free cash flow indicates the cash generated from operations and tax benefits attributable to stock option exercises, reduced by investments in fixed assets. We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business. We believe this is a common financial measure useful to further evaluate the results of operations. IDEXX Laboratories, Inc. and Subsidiaries Common St
'/>"/>
SOURCE IDEXX Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. IDEXX Laboratories to Present at JPMorgan Healthcare Conference
2. IDEXX Laboratories to Release 2007 Fourth Quarter and Full-Year Financial Results
3. IDEXX Laboratories Announces Fourth Quarter Results
4. IDEXX Laboratories Announces Increase in Share Repurchase Program
5. IDEXX Laboratories to Release 2008 First Quarter Financial Results
6. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
7. IDEXX Laboratories Names William Brown Corporate Vice President
8. IDEXX Laboratories to Release 2008 Fourth Quarter and Full-Year Financial Results
9. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
10. IDEXX Laboratories to Release 2009 First Quarter Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... Speaker Nancy Pelosi r...s in the Affordable Health Care for America Ac... and reduce Medicare Part D costs for people livin...urday by a vote of 220 to 215: ,, "Effective d...ty of life for thousands of Americans living with ...
(Date:11/9/2009)...d to transform our current campaign finance system... -- Members of Congress who noted "no" on health c...ceived $2.3 million more in campaign donations fro...in favor of the legislation to overhaul of the nat...leased by a coalition of campaign reform groups. ,...
(Date:11/9/2009)...ble in French . , , Montreal, November 9, 20...emale. In human bodies trillions of cells are coup... are composed. Yet these don,t come in twos, they...cause these complex cell networks are the backbone...ed for ways to splice cell clusters down to their ...
(Date:11/9/2009)... 2009 The first human embryonic stem cell treatme...shown to restore limb function in rats with neck s...he clinical trial to include people with cervical ...istration gave Geron Corp. of Menlo Park, Calif., ...viduals with thoracic spinal cord injuries, which ...
(Date:11/9/2009)...m risks, but not all agree , , MONDAY, N...aline solution might have soothing short-term bene... infections in the long run by stripping your nose... nose, we are removing the bad mucus but, unfortun...ntains the antimicrobial agents as well," said Dr....
Breaking Medicine News(10 mins):Health News:Pelosi Applauds Provisions in Health Bill to Improve Access to Care, Medications for People Living With HIV/AIDS 2Health News:'No' Votes on Health Care Bill Received $2.3 Million More from Health Insurance Industry 2Health News:UCI embryonic stem cell therapy restores walking ability in rats with neck injuries 2Health News:Sinus Rinses May Do More Harm Than Good 2Health News:Sinus Rinses May Do More Harm Than Good 3
...id arthritis (RA) face different treatment options...g . Two new studies examined patients decisions re...found that most RA patients are reluctant to chang...advances in RA treatment include multi-drug therap...
... Anthonys ability to walk. He and his mother feare...fined to a wheelchair. As is the case with...isorder, Anthony was left with few options and his...David M. Scher, M.D., a pediatric orthopedic surge...
...ted marketing authorization for INVEGA(TM) (palipe...ipsychotic medication for the treatment of schizo...y designed to deliver paliperidone - the active in... compared to placebo in helping many patients cont...
...ning have found that boys and girls are different ... However, they have suggested that this dissimil...ids from co-educational to segregated schools, or ...ching their teachers about the differences. ...
..."decrypting" an enzyme's function from its structu...e to drug discovery. Led by UCSF's Brian ...ge of Medicine, and Frank Raushel of Texas A and M... Shoichet says if the new strategy works with othe...
...n the last six years, death rates and heart failur...n sharply- most likely because of better treatmen...g trend parallels the growing use of cholesterol-l... professor at the University of Edinburgh: These r...
Other Medicine News:Health News:Alternative Treatments for Arthritis 2Health News:Alternative Treatments for Arthritis 3Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 2Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 3Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 2Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 3Health News:Boys and Girls are Different by Nature and Learn in Different Ways 2Health News:"Decryption" of Enzyme's Functions Paves Way for Future Drug Discovery 2Health News:Hearts Saved As Doctors Put Cutting Edge Discoveries to Use 2Health News:Hearts Saved As Doctors Put Cutting Edge Discoveries to Use 3
(Date:11/9/2009)...wire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT )...athologists, oncologists and the pharmaceutical in...ke presentations at two upcoming investor conferen... will be made at the Lazard Capital Markets Sixth ...sday, November 17. The conference will be held at ...
(Date:11/7/2009)...re/ -- Most patients with hereditary angioedema (H...g HAE attack giving the patients sufficient time t...sociated with that attack, according to survey fin... of Allergy, Asthma & Immunology (ACAAI) Annua...atigue and nausea, which occur frequently before a...
(Date:11/6/2009).... 6 In consultation with the U.S. ...r Healthcare, Division of McNEIL-PPC, Inc., is ini...product lots of TYLENOL® Arthritis Pain Caple...PEN CAP. McNeil is initiating the recall after ide...ated with these lots that led to a small number of...
Breaking Medicine Technology:Clarient to Present at Upcoming Healthcare Investor Conferences in New York City 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 3McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Ash Stevens Plans 246 Million Facility Expansion to Bolster CMC Capabilities 14293 1Ash Stevens Plans 246 Million Facility Expansion to Bolster CMC Capabilities 14293 2Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 1Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 2Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 4Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 5Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 6Have a Healthier Halloween with Tigers Milk 28R 29 58516 1Have a Healthier Halloween with Tigers Milk 28R 29 58516 2
Ethicon Medium Clip (insert only)
Ethicon Medium Clip
High Sensitivity CRP
LabDAQ3 Laboratory Information System
Medicine Products: